Quantcast

Latest Non-Hodgkin lymphoma Stories

2010-11-18 00:30:00

SEATTLE, Nov. 18, 2010 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that CTI's Marketing Authorization Application ("MAA") seeking approval for Pixuvri(TM) (pixantrone dimaleate) for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") was validated and accepted for review by the European Medicines Agency ("EMA"). Validation indicates that the application is complete and that the EMA's...

2010-11-12 08:09:59

(Ivanhoe Newswire)-- Long-term use of statins is unlikely to substantially increase or decrease overall cancer risk, but was associated with lowering risk of melanoma, endometrial cancer and non-Hodgkin lymphoma. "The lower risk of endometrial cancer and melanoma among long-term users has not been seen in most previous studies and was surprising," Eric J. Jacobs, Ph.D., strategic director of pharmacoepidemiology at the American Cancer Society, was quoted as saying. "The lower risk of...

2010-11-04 13:14:01

Weill Cornell researchers report on targeted therapy to repress protein mutations in diffuse large B-cell lymphomas Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive non-Hodgkin's lymphoma that accounts for approximately 40 percent of lymphomas among adults. If left untreated, it is fatal. The existing treatments have a cure rate that is slightly over 50 percent but destroy healthy cells along with the cancer cells. Researchers at Weill Cornell Medical College have found a...

2010-11-01 21:38:57

Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma. Although 60% of patients can be cured with a currently available combination therapy, this leaves a substantial number of patients without a cure. However, a team of researchers, led by Ari Melnick, at Weill Cornell Medical College, New York, has now identified a potential new combinatorial therapy for DLBCL. Specifically, the team found that combining an inhibitor of the protein BCL6 with either an...

2010-09-21 06:00:00

NEW YORK, Sept. 21 /PRNewswire/ -- While general awareness of lymphoma remains high, a new survey released today by the Lymphoma Research Foundation (LRF) reveals significant knowledge gaps among Americans about the disease, which is the most prevalent form of blood cancer in the United States. Survey results showed a high number of adults (86 percent) remain unaware that there are 67 different types of lymphoma - 61 types of non-Hodgkin lymphoma and six types of Hodgkin lymphoma. The...

2010-09-14 06:00:00

New National Survey Uncovers Patients' Need for More Lymphoma Resources to Effectively Participate in Their Care NEW YORK, Sept. 14 /PRNewswire-USNewswire/ -- The Cancer Support Community (CSC), uniting The Wellness Community and Gilda's Club Worldwide, announced today the launch of Framing Life With Lymphoma, a new educational program designed to enhance lymphoma patient and physician communication. This research-based program, led by the CSC with support from Cephalon, Inc., provides...

2010-09-07 04:35:02

Tokyo, Sept 7, 2010 - (JCN Newswire) - SymBio Pharmaceuticals Limited and Eisai Co., Ltd. announced today that Eisai's Singapore subsidiary Eisai (Singapore) Pte. Ltd. launched bendamustine hydrochloride ("bendamustine") in Singapore under the brand name Symbenda(R) as a treatment for low-grade non-Hodgkin's lymphoma and chronic lymphatic leukemia.Bendamustine is the subject of a license agreement concluded between the two companies in May 2009, in which SymBio granted Eisai the exclusive...

2010-08-30 08:00:00

BURLINGTON, Mass., Aug. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit...

2010-08-04 00:30:00

SEATTLE, Aug. 4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced it has filed for a Special Protocol Assessment ("SPA") with the U.S. Food and Drug Administration ("FDA") for the design of its new phase III trial of pixantrone for patients with relapsed or refractory aggressive B-Cell non-Hodgkin's lymphoma ("NHL"). In the filing, CTI proposed to the FDA that the randomized study will compare pixantrone plus rituximab against the current...

2010-07-27 08:00:00

WHITE PLAINS, N.Y. and CAMBRIDGE, Mass., July 27 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Shape Pharmaceuticals announced today that they have entered into a partnership to advance Shape's novel, topical treatment for cutaneous T-Cell lymphoma (CTCL) into clinical development. The compound, SHP-141, is a first-in-class topical histone deacetylase inhibitor with the potential to treat both early- and late-stage CTCL. Through the partnership, LLS will provide funding of...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related